查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080358

分子診斷市場：2026-2032年全球市場預測（按服務類型、技術、檢體類型、檢測類型、應用和最終用戶分類）

Molecular Diagnostics Market by Offering, Technology, Specimen Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，分子診斷市場規模將達到 342.7 億美元，複合年成長率為 9.70%。

主要市場統計數據
基準年 2025 179.1億美元
預計年份：2026年 196.1億美元
預測年份 2032 342.7億美元
複合年成長率 (%) 9.70%

分子診斷正從一項專門的檢測領域轉變為精準醫療、公共衛生監測和生物製藥開發的核心支柱。 PCR、RT-PCR、數位PCR、次世代定序、液態生物檢體、伴隨診斷和即時分子檢測的臨床價值正在推動感染疾病、腫瘤、遺傳疾病、生殖醫學和抗菌素抗藥性管理等領域的需求。

循證推動要素依然強勁。國際癌症研究機構（IARC）報告稱，2022年全球新增癌症病例約2000萬例，而世界衛生組織（WHO）則強調結核病、愛滋病、病毒性肝炎和抗生素抗藥性是需要準確快速檢測的持續優先事項。在醫療保健系統中，分子診斷不再只是一項可有可無的檢查室支出，而是一項策略性投資領域，旨在改善早期發現、治療選擇、疫情應對和治療進展監測。

分子診斷領域的變革性變化

分子診斷領域正經歷變革，這得益於去中心化、自動化、基於症候群的檢測以及從單分析物檢測到多檢測和定序工作流程的轉變。雖然新冠疫情加速了全球分子偵測能力的提升，但其帶來的長期變化更為深遠。如今，醫院、實驗室和公共衛生機構正利用分子診斷工具來診斷呼吸道感染疾病、敗血症、腫瘤、移植監測、藥物基因組學以及罕見疾病。

人工智慧的累積影響

人工智慧 (AI) 對整體分子診斷領域都產生了累積的影響，有助於改進檢測設計、突變解讀、品管、檢查室工作流程最佳化以及支援臨床決策。人工智慧在次世代定序中發揮著特別關鍵的作用，其演算法能夠幫助確定突變的優先順序、解讀複雜的基因組特徵，並將分子檢測觀察與實證治療方案聯繫起來。

關鍵區域洞察

亞太地區是分子診斷領域發展最快的地區之一，這主要得益於中國、印度、日本、韓國、澳洲和東協市場醫院網路的不斷擴張、日益沉重的癌症負擔、感染疾病監測的需求以及基因組學領域的投資。各國支持結核病檢測、病毒性疾病監測、癌症篩檢和罕見疾病診斷的計畫正在推動對PCR、NGS和分散式分子診斷平台的需求。北美地區憑藉先進的檢查室基礎設施、FDA批准和檢查室自主開發的檢測生態系統、癌症伴隨診斷、公共衛生定序以及生物製藥行業的強勁需求，仍然是創新和保險報銷的關鍵標竿。

關鍵小組洞察

隨著印尼、泰國、越南、馬來西亞、新加坡和菲律賓等國加大對醫院診斷、感染疾病控制、腫瘤學和檢查室現代化建設的投入，東協地區的需求正在不斷成長。海灣合作理事會（GCC）國家也正透過精準醫療計劃、三級醫療服務的擴展、婚前和新生兒篩檢計畫以及支持遺傳疾病、癌症篩檢和人口健康規劃的國家基因組舉措，推動分子診斷的發展。

主要國家的概況

美國憑藉先進的參考檢查室、FDA核准的檢測方法、腫瘤學領域的次世代定序（NGS）、液態生物檢體、新生兒篩檢以及伴隨診斷的應用，引領分子診斷領域的創新。加拿大受益於其公共衛生檢查室、基因組學舉措和協調一致的感染疾病監測體系的優勢，而墨西哥和巴西則正在擴展其私人診斷網路、醫院分子檢測和感染疾病應對能力。英國、德國、法國、義大利和西班牙的特點在於其各自的醫療保健系統、癌症防治、對抗抗生素抗藥性的優先措施以及體外醫療設備法規（IVDR）下的證據要求。同時，俄羅斯在傳染病檢查、癌症診斷和醫院分子檢測流程方面保持著強勁的需求。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床驗證、在病患管理、保險報銷和工作流程效率方面具有明確效用的分子診斷技術。檢測產品組合應兼顧高通量傳染病檢查與腫瘤學、藥物基因體學、生殖醫學、抗生素抗藥性和移植等領域的高價值應用，同時平台應支援自動化、互通性、從樣本到結果的工作流程以及可擴展的檢測菜單。

調查方法

本執行摘要基於來自公共衛生、監管、臨床和行業領域可靠來源的二手研究，包括世界衛生組織 (WHO)、國際癌症研究機構 (IARC)、美國疾病控制與預防中心 (CDC)、美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA)、經濟合作暨發展組織 (OECD)、世界銀行、國家衛生機構、歐洲藥物管理局 (EMA)、經濟合作暨發展組織 (OECD)、世界銀行、國家衛生機構、研究機構、臨床指導機構的臨床指導機構的臨床指導文件。檢驗重點在於已驗證的需求資訊來源、疾病負擔指標、監管趨勢、技術採納模式以及區域特定醫療保健基礎設施徵兆。

結論

分子診斷正朝著更主導和數位化驅動的階段發展，臨床價值、法規遵循、自動化和數據解讀將成為關鍵的競爭優勢。該領域的應用範圍已不再局限於疫情期間的檢測，而是擴展到腫瘤學、感染疾病、基因檢測、伴隨診斷、抗菌藥物抗藥性管理和公共衛生監測等領域的永續應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 分子診斷市場：依產品/服務分類

  • 裝置
  • 試劑和試劑盒
  • 軟體服務

第8章 分子診斷市場：依技術分類

  • 螢光原位雜合反應
  • 質譜分析
  • 微陣列分析
  • 次世代定序
    • EXOME定序
    • RNA定序
    • 標靶定序
    • 全基因測序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 多重PCR
    • 即時PCR

第9章 分子診斷市場：依檢體類型分類

  • 血
  • 腦脊髓液（CSF）
  • 鼻咽拭子
  • 唾液
  • 航班
  • 組織切片檢查
  • 尿

第10章 分子診斷市場：依檢測類型分類

  • 照護現場
  • 檢查室基地

第11章 分子診斷市場：依應用分類

  • 基因檢測
    • 基因帶原檢測
    • 診斷測試
    • 預測性測試
  • 感染疾病
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 腫瘤學
    • 液態切片
    • 微量殘存疾病
    • 組織切片檢查
  • 產前檢查
    • 侵入性
    • 非侵入性

第12章 分子診斷市場：依最終用戶分類

  • 學術研究機構
  • 診斷檢查室
  • 醫院和診所

第13章 分子診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 分子診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 分子診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories Inc.
  • Adaptive Biotechnologies Corporation
  • ADT Biotech Co., Ltd.
  • Agena Bioscience, Inc.
  • AstraZeneca plc
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis Group NV
  • bioMerieux SA
  • Bioneer Corporation
  • Castle Biosciences, Inc.
  • Danaher Corporation
  • Diasorin Sp, A.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Genomadix Inc.
  • Grifols SA
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Meridian Bioscience, Inc.
  • Myriad Genetics, Inc.
  • Oxford Gene Technology by Sysmex Corporation
  • QIAGEN NV
  • Siemens Healthineers AG
  • Source BioScience
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market is projected to grow by USD 34.27 billion at a CAGR of 9.70% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.91 billion
Estimated Year [2026] USD 19.61 billion
Forecast Year [2032] USD 34.27 billion
CAGR (%) 9.70%

Molecular diagnostics is moving from a specialized laboratory discipline to a core pillar of precision medicine, public health surveillance, and biopharma development. Demand is supported by the clinical value of PCR, RT-PCR, digital PCR, next-generation sequencing, liquid biopsy, companion diagnostics, and point-of-care molecular testing across infectious disease, oncology, inherited disease, reproductive health, and antimicrobial resistance management.

Evidence-based demand drivers remain strong. IARC reported nearly 20 million new cancer cases globally in 2022, while the WHO has highlighted tuberculosis, HIV, viral hepatitis, and antimicrobial resistance as persistent priorities requiring accurate and timely testing. For healthcare systems, molecular diagnostics improves early detection, therapy selection, outbreak response, and treatment monitoring, making it a strategic investment area rather than a discretionary laboratory expense.

Transformative Shifts in the Molecular Diagnostics Landscape

The molecular diagnostics landscape is being reshaped by decentralization, automation, syndromic testing, and the shift from single-analyte assays to multiplex and sequencing-based workflows. COVID-19 accelerated molecular testing capacity worldwide, but the longer-term shift is broader: hospitals, reference laboratories, and public health agencies are now applying molecular tools to respiratory infections, sepsis, oncology, transplant monitoring, pharmacogenomics, and rare disease diagnosis.

Regulation is also transforming market behavior. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence and post-market surveillance, while the United States continues to scrutinize laboratory-developed tests and companion diagnostic pathways. These changes favor manufacturers and laboratories with validated assays, scalable quality systems, strong clinical evidence, and integrated informatics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across molecular diagnostics, improving assay design, variant interpretation, quality control, laboratory workflow optimization, and clinical decision support. AI is especially relevant in next-generation sequencing, where algorithms help prioritize variants, interpret complex genomic signatures, and connect molecular findings with evidence-based therapy options.

The impact is not limited to analytics. AI-enabled automation can reduce manual review, support capacity planning, improve sample routing, and detect anomalies in high-throughput laboratories. However, adoption must be governed by transparent validation, cybersecurity, data provenance, bias monitoring, and alignment with evolving oversight frameworks, including FDA activity on AI-enabled medical devices and the EU AI Act.

Key Regional Insights

Asia-Pacific is one of the fastest-evolving molecular diagnostics regions due to expanding hospital networks, rising cancer burden, infectious disease surveillance needs, and investment in genomics across China, India, Japan, South Korea, Australia, and ASEAN markets. National programs supporting tuberculosis testing, viral disease surveillance, cancer screening, and rare disease diagnosis are strengthening demand for PCR, NGS, and decentralized molecular platforms. North America remains the leading innovation and reimbursement reference point, supported by advanced laboratory infrastructure, FDA-cleared and laboratory-developed testing ecosystems, oncology companion diagnostics, public health sequencing, and strong biopharma demand.

Europe is shaped by IVDR implementation, national health technology assessment discipline, established screening programs, and growing use of molecular oncology and antimicrobial resistance testing. Latin America is gaining momentum through private laboratory consolidation, expanding hospital access, and infectious disease testing needs in Brazil, Mexico, and other urban healthcare systems. The Middle East is investing in national genomics, tertiary hospitals, and precision medicine programs, particularly across GCC countries, while Africa's opportunity is closely tied to tuberculosis, HIV, malaria, emerging pathogen surveillance, outbreak preparedness, and scalable point-of-care molecular diagnostics suited to decentralized care settings.

Key Group Insights

ASEAN demand is expanding as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines invest in hospital diagnostics, infectious disease preparedness, oncology capacity, and laboratory modernization. The GCC is advancing molecular diagnostics through precision medicine initiatives, tertiary care expansion, premarital and newborn screening programs, and national genome initiatives that support inherited disease, cancer testing, and population health planning.

The European Union is defined by IVDR compliance, cross-border evidence standards, reimbursement scrutiny, and the need for clinically validated assays that can meet post-market performance requirements. BRICS countries combine large patient populations with growing local manufacturing, genomics capacity, and public health priorities in tuberculosis, cancer, and infectious disease surveillance. G7 markets remain the benchmark for high-complexity molecular testing, companion diagnostics, laboratory automation, and advanced reimbursement models, while NATO economies also place strategic value on biosecurity, pathogen surveillance, and resilient diagnostic supply chains.

Key Country Insights

The United States leads in molecular diagnostics innovation through advanced reference laboratories, FDA-cleared assays, oncology NGS, liquid biopsy, newborn screening, and companion diagnostic adoption. Canada benefits from public health laboratory strength, genomics initiatives, and coordinated infectious disease surveillance, while Mexico and Brazil are expanding private diagnostic networks, hospital-based molecular testing, and infectious disease capabilities. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, cancer strategies, antimicrobial resistance priorities, and IVDR-driven evidence requirements, while Russia maintains demand across infectious disease testing, oncology diagnostics, and hospital-based molecular workflows.

China is scaling domestic IVD manufacturing, oncology testing, sequencing capacity, and public health molecular infrastructure, while India is expanding affordable PCR, tuberculosis testing, oncology diagnostics, and decentralized laboratory access under a healthcare system that continues to prioritize infectious disease control and cancer care. Japan and South Korea remain leaders in automation, oncology diagnostics, genomic medicine, and high-quality clinical laboratory standards. Australia benefits from mature reimbursement structures, public health surveillance, established genetic testing pathways, and strong adoption of advanced infectious disease and inherited disease testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated molecular diagnostics with clear utility in patient management, reimbursement, and workflow efficiency. Assay portfolios should balance high-volume infectious disease testing with higher-value oncology, pharmacogenomics, reproductive health, antimicrobial resistance, and transplant applications, while platforms should support automation, interoperability, sample-to-answer workflows, and scalable menu expansion.

Commercial strategy should align with regional regulation and evidence expectations. Organizations should invest in IVDR readiness, FDA engagement, companion diagnostic partnerships, AI governance, cybersecurity, data privacy, decentralized testing models, and supply chain resilience for reagents and consumables. Laboratories should reduce turnaround time through integrated workflows and build partnerships with hospitals, payers, public health agencies, and biopharma sponsors to demonstrate measurable clinical and operational outcomes.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources, including the WHO, IARC, CDC, FDA, EMA, OECD, World Bank, national health agencies, peer-reviewed medical literature, clinical guideline bodies, and publicly available regulatory documentation. The analysis emphasizes verified demand drivers, disease burden indicators, regulatory developments, technology adoption patterns, and region-specific healthcare infrastructure signals.

Insights were synthesized using a triangulation approach that compares disease burden, installed laboratory capacity, regulatory requirements, reimbursement maturity, procurement behavior, technology readiness, and public health priorities. The methodology prioritizes evidence-backed interpretation over speculative forecasting and is designed to support strategic planning for molecular diagnostics manufacturers, laboratories, investors, and healthcare decision-makers.

Conclusion

Molecular diagnostics is entering a more evidence-driven and digitally enabled phase, where clinical value, regulatory compliance, automation, and data interpretation determine competitive advantage. The field is expanding beyond pandemic-era testing into durable applications across oncology, infectious disease, genetic testing, companion diagnostics, antimicrobial resistance management, and public health surveillance.

Organizations that combine validated assays, AI-supported interpretation, strong quality systems, interoperable platforms, and region-specific access strategies will be best positioned to capture growth opportunities without relying on speculative demand assumptions. As healthcare systems prioritize earlier diagnosis and targeted treatment, molecular diagnostics will remain essential to precision medicine, resilient public health infrastructure, and measurable patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Molecular Diagnostics Market, by Offering

  • 7.1. Instruments
  • 7.2. Reagents & Kits
  • 7.3. Software & Services

8. Molecular Diagnostics Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Mass Spectrometry
  • 8.3. Microarray Analysis
  • 8.4. Next-Generation Sequencing
    • 8.4.1. Exome Sequencing
    • 8.4.2. RNA Sequencing
    • 8.4.3. Targeted Sequencing
    • 8.4.4. Whole Genome Sequencing
  • 8.5. Polymerase Chain Reaction
    • 8.5.1. Digital PCR
    • 8.5.2. Multiplex PCR
    • 8.5.3. Real-Time PCR

9. Molecular Diagnostics Market, by Specimen Type

  • 9.1. Blood
  • 9.2. Cerebrospinal Fluid (CSF)
  • 9.3. Nasal/Throat Swabs
  • 9.4. Saliva
  • 9.5. Stool
  • 9.6. Tissue Biopsies
  • 9.7. Urine

10. Molecular Diagnostics Market, by Test Type

  • 10.1. Point Of Care
  • 10.2. Laboratory Based

11. Molecular Diagnostics Market, by Application

  • 11.1. Genetic Testing
    • 11.1.1. Carrier Testing
    • 11.1.2. Diagnostic Testing
    • 11.1.3. Predictive Testing
  • 11.2. Infectious Disease
    • 11.2.1. Bacterial
    • 11.2.2. Parasitic
    • 11.2.3. Viral
  • 11.3. Oncology
    • 11.3.1. Liquid Biopsy
    • 11.3.2. Minimal Residual Disease
    • 11.3.3. Tissue Biopsy
  • 11.4. Prenatal Testing
    • 11.4.1. Invasive
    • 11.4.2. Non-Invasive

12. Molecular Diagnostics Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics

13. Molecular Diagnostics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Molecular Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Molecular Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories Inc.
  • 17.2. Adaptive Biotechnologies Corporation
  • 17.3. ADT Biotech Co., Ltd.
  • 17.4. Agena Bioscience, Inc.
  • 17.5. AstraZeneca plc
  • 17.6. Becton, Dickinson and Company
  • 17.7. BGI Genomics Co., Ltd.
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Bio-Techne Corporation
  • 17.10. Biocartis Group NV
  • 17.11. bioMerieux SA
  • 17.12. Bioneer Corporation
  • 17.13. Castle Biosciences, Inc.
  • 17.14. Danaher Corporation
  • 17.15. Diasorin S.p,A.
  • 17.16. Exact Sciences Corporation
  • 17.17. F. Hoffmann-La Roche AG
  • 17.18. Genomadix Inc.
  • 17.19. Grifols S.A.
  • 17.20. Guardant Health, Inc.
  • 17.21. Hologic, Inc.
  • 17.22. Illumina, Inc.
  • 17.23. Laboratory Corporation of America Holdings
  • 17.24. Meridian Bioscience, Inc.
  • 17.25. Myriad Genetics, Inc.
  • 17.26. Oxford Gene Technology by Sysmex Corporation
  • 17.27. QIAGEN N.V.
  • 17.28. Siemens Healthineers AG
  • 17.29. Source BioScience
  • 17.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLEX PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLEX PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLEX PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL REAL-TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL REAL-TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REAL-TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STOOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STOOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LABORATORY BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LABORATORY BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LABORATORY BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARRIER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARRIER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARRIER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NON-INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 229. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 231. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 236. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 268. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 270. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 275. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 278. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 281. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 283. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 288. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 291. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 358. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 359. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 360. GERMANY MOLECULAR DIAGNOSTICS MARK